TWi Biotechnology, Inc. (6610.TWO)
TWD 13.9
(-4.14%)
TWD 13.9
(-4.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -134.21 Million | -60.24 Million | -34.46 Million | -62.57 Million | -97.84 Million |
| Net Income | -170.68 Million | -76.17 Million | -15.29 Million | -100.5 Million | -111.52 Million |
| Depreciation & Amortization | 9.73 Million | 10.35 Million | 11.09 Million | 11.67 Million | 10.63 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 5.5 Million | 3.08 Million | - | - | - |
| Change in working capital | 21.23 Million | 2.5 Million | -30.26 Million | 27.57 Million | 3.72 Million |
| Other non-cash items | -2.75 Million | -1.62 Million | -1.32 Million | -3.42 Million | -683 Thousand |
| Investing Cash Flow | -171.85 Million | 34.3 Million | 161.64 Million | 71.81 Million | -26.59 Million |
| Investments in PPE | 134.21 Million | - | -30.22 Million | -30 Million | -243 Thousand |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -171.85 Million | -1 Million | -35.3 Million | -227.2 Million | - |
| Sales/Maturities of investments | - | 35.3 Million | 227.2 Million | 329.01 Million | - |
| Other Investing Activities | -171.85 Million | 34.3 Million | -32 Thousand | 71.81 Million | 2000.00 |
| Financing Cash Flow | 297.5 Million | -2.49 Million | -2.46 Million | -2.47 Million | -2.64 Million |
| Debt repayment | -2.49 Million | -2.49 Million | -2.46 Million | -2.47 Million | -2.64 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 300 Million | - | - | - | - |
| Other Financing Activities | 300 Million | - | - | - | - |
| Accounts receivables | 133 Thousand | 3.56 Million | -3.4 Million | 7.02 Million | 7.22 Million |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | 2.34 Million | 401 Thousand | 653 Thousand |
| Other working capital | 21.1 Million | -1.05 Million | 867 Thousand | -7.47 Million | -4.14 Million |
| Cash at beginning of period | 160.4 Million | 188.83 Million | 64.11 Million | 57.36 Million | 184.44 Million |
| Cash at end of period | 151.83 Million | 160.4 Million | 188.83 Million | 64.11 Million | 57.36 Million |
| Capital Expenditure | 134.21 Million | - | -30.22 Million | -30 Million | -243 Thousand |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -8.56 Million | -28.43 Million | 124.71 Million | 6.75 Million | -127.08 Million |
| Free Cash Flow | - | -60.24 Million | -64.68 Million | -92.57 Million | -98.08 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -48.25 Thousand | -48.25 Thousand | -65 Thousand | -170.68 Million | -65 Thousand | -20.33 Thousand |
| Depreciation & Amortization | 2426.50 | 2426.50 | 2426.50 | 9.73 Million | 2426.50 | 2441.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 2750.00 | 5.5 Million | 2750.00 | - |
| Change in working capital | 320.50 | 320.50 | 11.08 Thousand | 21.23 Million | 11.08 Thousand | -471.00 |
| Other non-cash items | -438.50 | -438.50 | -4.00 | -2.75 Million | -4.00 | 2.00 |
| Investing Cash Flow | 69.7 Thousand | 69.7 Thousand | -85.92 Thousand | -171.85 Million | -85.92 Thousand | - |
| Investments in PPE | -154.00 | -154.00 | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -171.85 Million | - | - |
| Sales/Maturities of investments | 139.72 Million | - | - | - | - | - |
| Other Investing Activities | 69.86 Thousand | 69.86 Thousand | -85.92 Thousand | -171.85 Million | -85.92 Thousand | - |
| Financing Cash Flow | -531.00 | -531.00 | 149.38 Thousand | 297.5 Million | 149.38 Thousand | -630.00 |
| Debt repayment | - | - | - | -2.49 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 300 Million | - | - |
| Other Financing Activities | -531.00 | -531.00 | 149.38 Thousand | 300 Million | 149.38 Thousand | -630.00 |
| Accounts receivables | -80.00 | -80.00 | -48.00 | 133 Thousand | -48.00 | 114.50 |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 400.50 | 400.50 | 11.13 Thousand | 21.1 Million | 11.13 Thousand | -585.50 |
| Cash at beginning of period | 151.83 Million | - | - | 160.4 Million | - | - |
| Cash at end of period | 23.23 Thousand | 23.23 Thousand | 14.7 Thousand | 151.83 Million | 14.7 Thousand | -18.99 Thousand |
| Capital Expenditure | -154.00 | -154.00 | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -151.81 Million | 23.23 Thousand | 14.7 Thousand | -8.56 Million | 14.7 Thousand | -18.99 Thousand |
| Free Cash Flow | -46.1 Thousand | -46.1 Thousand | -48.74 Thousand | -134.21 Million | -48.74 Thousand | -18.36 Thousand |
JPASSOCIAT
8074
GOLLQ
0984
MNOIY
EMP